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Patients and method: Data of 82 patients with macromastia undergoing ORM for breast cancer
between 1996 and 2011 were retrospectively examined and evaluated with regard to oncolog-
ical results.
Results: The median age was 50 years. The median follow-up was 121 months (range 28e212
months). The median breast volume was 1402 cm3 and the median weight of excised breast
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was 8.7%. The 10-year overall survival rate was 82.2% and the disease-free survival rate was
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Conclusions: From the standpoint of local disease control and long-term observation, ORM can
be considered a very safe and acceptable treatment for early stage breast cancer in women
with macromastia.
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Breast-conserving surgery (BCS) is the standard treatment
for early stage breast cancer, but this procedure is associ-
ated with certain oncological and cosmetic problems, such
as large breast size, positive margins, tumor/breast volume
ratio, problems associated with radiotherapy (RT), and
patient dissatisfaction. The frequency of macromastia in
breast cancer patients undergoing BCS is 40%.1 In Losken
et al’s meta-analysis,2 the rate of positive margins after
BCS was 20.6%. Some problems have been reported with RT
dose homogeneity in post-BCS patients with large breasts,3
and aesthetic concerns in post-BCS patients have reached
30%.4 Indeed, postoperative RT problems, aesthetic con-
cerns, and overall patient satisfaction rate are considered
relative contraindications for choosing BCS in breast cancer
cases with macromastia.
Bilateral oncoplastic reduction mammoplasty (ORM)
combines the techniques of tumorectomy and bilateral
breast reduction. Thus, a tumor can be excised with wider
margins, and the effectiveness of RT on a reduced breast
increases.5 Because screening programs and adjuvant
therapies indicate that patients with breast cancer have a
longer life expectancy, breast aesthetics and quality of life
have become more critical. Bilateral reduction mammo-
plasty improves quality of life.6
Despite the increase in the number of ORM studies,
there are no data showing long-term oncological results for
ORM in patients with macromastia, although this is by far
the more common procedure. Therefore, we examined the
10-year results of women with macromastia undergoing
ORM for early stage breast cancer in terms of oncological
results. The principal aim of this study was to evaluate the
efficacy of long-term oncological local control in ORM. This
was gauged by positive margins, close margins, and ipsi-
lateral recurrence. Regional recurrence was not consid-
ered. The secondary aim was to determine the impact of
ORM on 10-year overall survival (OS) and disease-free sur-
vival (DFS) rates.2. Patients and methods
A retrospective review of the medical records of consecu-
tive 82 patients with macromastia undergoing concomitant
ORM between January 1996 and May 2011 was carried out.
According to the 2010 American Joint Committee on Can-
cer/Union for International Cancer Control breast cancer
staging system, patients with Stages 1 and 2 were included
in this study. Patients with in situ Stage 3 breast cancer, or
breast volume less than 1000 cm3 were excluded. Eight
patients who underwent ORM withdrew from observations
and were excluded from the study. Macromastia was
defined as breast volume more than 1000 cm3. The cases
were examined for demographics, macromastia, operative
and oncologic outcomes, complications, and adjuvant
therapy. All cases were discussed and treatment options
were initially planned in multidisciplinary weekly meetings.
Written informed consent was obtained for the surgical
procedure. This study was approved by the local ethics
committee.2.1. Patient evaluation and operative techniques
Routine preoperative oncological screening was carried out
in all patients diagnosed with breast cancer. Wire locali-
zation was used on nonpalpable breast lesions during ul-
trasound and/or mammography. Preoperative magnetic
resonance imaging (MRI) was performed in nine cases.
Breast volume of all patients was measured using a Gross-
maneRoudner device.7 Breast asymmetry was accepted as
a disparity if breast volume was over 10%.
During the preoperative evaluation, we determined the
tumor quadrants to be excised, the choice of nipple areola
complex (NAC) flap, access to the axilla, choice of skin
incision, and the estimated volume of breast tissue to be
removed. Similar decisions were made for the contralateral
breast. Tumors were excised with a minimum margin of
1.5 cm. In the final pathological evaluation, any margin less
than 2 mm was accepted as a positive margin. Intra-
operative margin control was achieved using frozen sec-
tions with specimen mammography for multifocal tumors,
and all re-excisions were performed immediately. The only
skin removed included biopsy-incision scars and skin-
covering tumors closer than 1 cm to the surface. Nipple
resection was performed in tumors closer than 2 mm to the
nipple. Metal clips were placed in the tumor bed as a guide
for RT, and the orientation of the excised specimen was
marked. Similar procedures were carried out simulta-
neously on the contralateral breast to achieve symmetry.
The ipsilateral breast was left 10% larger to allow for
shrinkage during RT. At least two members of the strong
five-member surgical team were present at each operation.
The Wise pattern incision was chosen for its ease of
axillary access, flap alternatives, and ease of breast
reconstruction. We preferred the vertical incision in cases
of macromastia less than 1300 cm3 to minimize the incision.
Our choice of NAC carrying the pedicle was based on
forming a pedicle in the breast section furthest from the
tumor. A free nipple graft was used in cases where the NAC
distance was more than 35 cm. In cases of nipple involve-
ment, we performed a central resection, followed by a
Grisotti flap reconstruction. Sentinel lymph node biopsy
(SLNB) or four to eight lymph node sampling was imple-
mented in clinically node-negative patients, and axillary
dissection (AD; Levels 1 and 2) was performed in node-
positive cases. Complications were recorded as early (<2
months) and late (>2 months).
Standard RT was applied 3 weeks postoperatively with
50 Gy to the whole breast and a 10-Gy boost to the tumor
bed. Of the total patients in this study, 24 were administered
chemotherapy (CT), 25 were administered both CT and hor-
mone therapy (HT), and 33 received only HT. The CT regimen
was fluorouracil, epirubicin, and cyclophosphamide (FEC) in
21 patients; cyclophosphamide, methotrexate, and fluoro-
uracil in nine; adriamycin (doxorubicin) and cyclophospha-
mide (AC) in seven; FEC þ taxane in seven; and AC þ taxane
in five patients. Tamoxifen was used for HT in 47 cases, and
aromatase inhibitors were used in 16 cases. In addition, 16
Cerb-B2-positive cases were treated with trastuzumab. Pa-
tients were followed by surgeons and medical oncologists
every 4 months for the first 2 years, every 6 months for the
following 3 years, and then on an annual basis.
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question survey.
1. Would you be prepared to undergo the same operation
again, if necessary?
(A) Yes (B) No (C) No comment
2. Would you recommend this operation to other women
with similar problems (macromastia and breast cancer)?
(A) Yes (B) No (C) No commentTable 1 Histology and tumor biology.
Biology n (%)
Tumor type
Ductal 59 (72)
Ductal þ DCIS 16 (19.5)
Lobular 5 (6.1)
Lobular þ DCIS 2 (2.4)
Tumor size, mm
0e5 4 (4.9)
6e10 9 (11.0)
11e20 29 (35.4)
21e50 40 (48.8)
Axilla
No 45 (54.9)
N mic 7 (8.5)
N1 (1e3) 30 (36.6)
ER or PR
Positive 56 (68.3)
Negative 14 (17.1)
Unknown 12 (14.6)
HER2/neu
Positive 16
Negative 30
Unknown 36
DCIS Z ductal carcinoma in situ; ER Z estrogen receptor;
PR Z progesterone receptor.2.2. Statistics
Data were analyzed using SPSS version 15 (SPSS Inc., Chi-
cago, IL, USA). DFS, locoregional, metastasis-free, and OS
rates were estimated using KaplaneMeier estimates, and
the patient and treatment groups were compared using the
log-rank test. Multivariate analyses were performed with
Cox proportional hazard models to test the differences
between groups. A value of p < 0.05 was considered sta-
tistically significant.
3. Results
3.1. Patient data
The median age was 50 years (range, 31e70 years). Median
body mass index was 28.9 kg/m2. At the time of diagnosis,
65 patients (79.3%) were postmenopausal and 17 patients
(20.7%) were premenopausal. As much as 12 (14.6%) pa-
tients had a family history of breast cancer, 11 patients had
diabetes mellitus, 10 had hypertension, and 14 (17%) were
smokers. The median length of the postoperative hospital
stay was 3.4 days, and the tumor was on the right side in 42
patients (53.6%). The median follow-up period was 121
months (range, 28e212 months).
3.2. Operative findings
The mean operation time was 124 minutes  25 minutes.
Quadrantectomy followed by oncoplastic reduction was
performed in the first 27 cases, and the tumor area was
excised en bloc in the next 55 cases. The Wise pattern was
implemented for the skin incision in 60 cases, and a vertical
incision was used in 22 cases. Most tumors were located in
the upper outer quadrant (n Z 25).
For reconstruction, 48 inferior, 17 superior-medial,
seven superior, four free nipple, four superior-lateral, and
three Grisotti flaps were used. Similar techniques were
used concomitantly on the contralateral breast. Intra-
operative frozen section and specimen radiography were
conducted in 48 (58%) and 43 (52%) cases, respectively. Two
patients underwent re-excision because of positive margins
seen during the frozen-section examination. Clips were
placed in the tumor bed in 56 cases. Fifty patients under-
went an SLNB intraoperatively before ORM for axillary
surgery. AD was performed in nine cases because of SLNB
positivity. Axillary samples were taken in eight cases. AD
was performed in 24 preoperative clinically node-positive
cases.3.3. Histopathological evaluation
The final pathological evaluation is summarized in Table 1.
The mean tumor size was 26 mm (range, 4e47 mm). The
median tumor margin distance measured in 61 patients was
16 mm (range, 8e46 mm). Multifocality was found in 12
cases and vascular invasion was found in 11 cases. We found
that 17 patients were Grade (G1), 27 were G2, and 12 were
G3. Positive margins were found in three cases (3.7%).
Because of positive margins in three cases, re-excisions
were performed, and a frozen section was evaluated. A
close margin was found in one patient (1.2%), in whom re-
excision was performed, but no tumor occurred in the
final histopathological evaluation. Two (2.4%) invasive
(ductal and lobular) cancers, four (4.9%) in situ cancers, and
six (7.4%) atypical ductal hyperplasia cases were recorded
during the histological evaluation of contralateral breasts.3.4. Complications
A total of 10 cases (12.2%) had early complications,
including suture-line dehiscence (n Z 4), seroma (n Z 3),
wound-site infection (n Z 2), and areola necrosis (n Z 1).
Adjuvant treatment was postponed for 10e20 days in the
four (4.9%) cases of incision opening and areola necrosis.
Late complications were seen in 12 cases (14.6%), including
the following: skin problems (color, scarring); fat necrosis
and fibrosis (re-excision was performed); impaired breast
shape (dog ear correction); breast hypertrophy (treated
with re-reduction), and chronic mastalgia. MRI was used
two times on average (range, 1e3) for 11 patients (13.4%)
with irregular breast symptoms. Fine-needle biopsy was
Table 3 Characteristics of patients with locoregional re-
currences, metastasis, and death.
LRR Metastasis Death
N 5 17 14
Tumor size (mm)
1e10 d 1 1
11e20 1 3 2
>20 4 13 9
ER/PR
Positive 1 8 6
Negative 2 6 5
Unknown 2 3 3
HER2/neu
Positive 2 5 3
Negative 2 7 7
Unknown 1 5 5
Surgical margin
Positive 1 2 2
Negative 4 15 12
ER Z estrogen receptor; LR Z locoregional recurrence;
PR Z progesterone receptor.
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Figure 1 Overall patient survival analysis (Stages 1 and 2).
44 M. Emiroglu et al.performed once or twice on eight patients (9.6%) with
clinically suspicious areas, and all were benign.
3.5. Oncology
Oncological results and survival rates are shown in Tables 2
and 3 and Figures 1 and 2. Four cases (4.9%) of isolated
breast recurrence were observed in the original cohort. The
median interval between the primary breast cancer diag-
nosis and axillary recurrence was 43 months (range, 18e106
months). Breast recurrence was seen 19 months post-
operatively in a patient whose positive margin led us to re-
excise the upper outer quadrant. Mastectomy and late-
stage transverse rectus abdominis myocutaneous recon-
struction was performed with the help of a plastic surgeon.
A wide re-excision was performed at the 21-month post-
operative follow-up visit, and a frozen section was obtained
for breast recurrence in a patient whose primary tumor had
been in the lower inner quadrant. One patient, who needed
axillary node sampling, developed an axillary recurrence 18
months postoperatively and underwent axillary clearance.
This patient had missed a dose of RT. Another patient who
had undergone axillary node sampling developed an axillary
recurrence after 18 months, and axillary clearance was
performed. Two incidences of ipsilateral recurrence 59
months and 106 months after the operation revealed
lobular carcinoma. In the first case, the recurrence was in
the same quadrant as the primary tumor, and concomitant
distant metastases developed. This patient received wide
local excision with CT and additional HT. In the second
case, the 72-year-old patient underwent wide excision of a
mass, and a frozen section was obtained with additional HT.
Distant metastases were diagnosed in 17 patients (20.7%)
over a median period of 83 months. Metastases were
located in the bone (n Z 5), bone and liver (n Z 5), bone
and lungs (n Z 3), liver (n Z 3), lungs (n Z 2), and brain
(n Z 1). A total of 14 patients received CT, eight patients
received HT (in addition to the first 5 years), and eight
patients received palliative RT for metastatic bone
involvement. Fourteen patients (17.1%) died after a mean
observation period of 108.1 months (range, 33e186
months); four of the five cases that developed locoregional
recurrence developed distant metastases, and three sub-
sequently died. Thirteen patients with metastatic cancer
died because of tumor dissemination, and one patient died
in a traffic accident.
3.6. Macromastia
The mean weight of breast tissue removed was 678 g.
Because four patients died and three patients refusedTable 2 Patients’ 5-year and 10-year oncologic results and sur
Stage N LR (%) RR (%)
Year 5 Year 10 Year 5 Ye
I 36 0 (0) 0 (0) 0 (0) 0
II 46 2 (4.1) 4 (8.7) 1 (2.2) 1
I þ II 82 2 (4.1) 4 (8.7) 1 (1.2) 1
DFS Z disease-free survival; LR Z local recurrence, OS Z overall subreast volume measurements, the final breast volume
evaluation was based on 65 patients. Table 4 summarizes
the macromastia data.
Responses to the short survey questions showed that 57
patients (93.4%) would choose this procedure again, two
patients (3.3%) would not, and two patients (3.3%) did not
comment. In addition, 59 patients (96.7%) would recom-
mend this procedure to a patient in a similar situation,
whereas two patients (3.3%) would not.vival rates.
DFS (%) OS (%)
ar 10 Year 5 Year 10 Year 5 Year 10
(0) 96.5 88.8 98.4 94.4
(2.2) 81.1 65.2 93.9 73.9
(1.2) 86.4 73.2 97.1 82.2
rvival; RR Z regional recurrence.
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Figure 2 Disease-free survival analysis (Stages 1 and 2).
Table 4 Characteristics of the patients with
macromastia.
Characteristics Preoperative Final
evaluation
p
N 82 65
Median BMI, kg/m2 28.9 (22e36) 32.1 (24e41)
Median breast volume, cm3
Right breast 1380 (100e1900) 890 (650e960)
Left breast 1420 (1050e2000) 875 (67e940)
Asymmetry (%) 14 (17.1) 6 (9.2) 0.04
BMI Z body mass index.
Oncoplastic reduction mammoplasty for breast cancer 454. Discussion
The main finding of this study was that the choice of
concomitant ORM BCS led to improved oncologic and
satisfaction outcomes in women with early breast cancer
and macromastia in terms of long-term results. This pro-
cedure was considered favorable by a large proportion of
the patient cohort.
4.1. Oncology
The use of ORM is highly suitable for treating breast cancer
in women with macromastia, and is efficient for localTable 5 Studies on ORM in patients with macromastia.
Reference n Follow-up,
mo
Stage/tumor
size, mm
Specimen,
g
Newman et al9 28 24 15 766
Chang et al10 37 d I, II 653
Munhoz et al11 74 22 d 610
Kronowitz et al12 41 36 d 626
Currie et al13 20 34 I, II 370
This study 82 121 I, II 679
ORM Z oncoplastic reduction mammoplasty.disease control. Similar studies of ORM for treating breast
cancer in women with macromastia reported positive
margins of 2.7e7.3% with breast recurrence rates of
0e4.9% (Table 5).9e13 However, these studies, with a me-
dian dissection material weight of 370e766 g, comprised
fewer cases and a shorter follow-up time. In a meta-
analysis, Losken et al2 reported positive margins in 12.4%
of ORM cases without macromastia, 12.2% for oncoplastic
flaps, and 20.6% for BCS alone. Local recurrence was re-
ported as 4.7% for ORM, 3.6% for oncoplastic flap, and 6.7%
for BCS alone. In an oncoplastic review, Haloua et al8 re-
ported positive margins and recurrence rates for the
oncoplastic flap procedure of 7e20% and 0e7%, respec-
tively. The National Cancer Institute (NCI) reported a local
recurrence rate of 18% over a 10-year period in patients
operated on with clean margins for Stage I and Stage II
breast cancer after BCS.14 Tanis et al15 reported a 10.1-year
locoregional recurrence rate of 11% after BCS for cancer
Stages IeIII. In our study, positive margins occurred in 3.7%
of cases, the breast recurrence rate was 4.9%, and the rate
of locoregional recurrence was 6.1%. We believe that these
low rates stemmed from the wide excision of nerves, tu-
mors, and breast parenchyma en bloc, as well as from the
use of intraoperative frozen section and specimen radiog-
raphy. Our data show that ORM with macromastia provided
better local control than BCS, oncoplastic breast surgery, or
oncoplastic reduction (OR) alone. In this study, two cases of
breast recurrence appeared at a delayed stage; it was
interesting that both cases were invasive lobular cancer.
The most important factor affecting local recurrence was a
positive margin. In situ cancer, multifocality, and an
extensive intraductal component were biological features
associated with recurrence. The type of procedure used
was not alone responsible for the outcome. Removing a
large volume of breast material together with the tumor
was associated with a better oncologic prognosis. Critics of
oncoplastic surgery suggest that as the tumor bed location
changes during breast reconstruction, there is a change in
location for RT, and consequently this may lead to the need
for larger RT doses.8,16 One study reported that breast
recurrence mainly developed at the primary tumor site in
patients undergoing ORM; therefore, RT should be directed
to that area.17 In our study, three of the four recurrence
incidents were in the primary tumor region, which would
support additional RT being applied to that area. Although
there are no reports of significant problems with post-
operative imaging of OMC patients, we found that addi-
tional imaging and biopsy were necessary.16,18Positive margin,
%
Recurrence,
%
Survival,
%
Complication,
%
7.1 0.0 96.0 35.7
2.7 0.0 100.0 16.2
2.7 0.0 100.0 32.4
7.3 4.9 100.0 34.1
5.9 0.0 d 25.0
3.7 4.9 82.2 26.6
46 M. Emiroglu et al.Our study established good reliability for the long-term
survival of women with macromastia undergoing ORM for
breast cancer. We did not compare survival rates with
similar studies and short follow-up periods (Table 5), but we
did compare them with long-term survival rates reported in
BCS procedures for breast cancer. An NCI study reported a
77% overall 10-year survival rate for Stage I and Stage II
breast cancers that received BCS with an additional RT dose
(15e20 Gy).14 The European Organization for Research and
Treatment reported an overall 10-year survival rate of 65%
after BCS treatment for early stage breast cancer with a 5-
cm tumor.19 Rietjens et al20 reported a 93% survival rate
over 74 months in a series of 148 cases with a median tumor
size of 22 mm. Our survival rates were similar to these
studies. We consider that there are no long-term oncolog-
ical problems for ORM in patients with breast cancer and
macromastia.
The histopathological evaluation of the contralateral
breast is crucial. Freedman et al21 reported a hidden cancer
rate of 0.3% in specimens from patients undergoing reduc-
tion surgery for macromastia, and a 3.6% rate in the
contralateral breast in patients with cancer and macro-
mastia. In our study, this rate was 6.1%. No suspicious areas
were detected on the preoperative imaging of these pa-
tients. Because breast cancer cannot always be detected
on preoperative imaging, great care should be taken during
the histopathological evaluation of a specimen from the
contralateral breast.4.2. Macromastia: Complications
It was found that women with macromastia and breast
cancer were very pleased with ORM outcomes. Because a
very large amount of breast tissue was removed in this
technique, complaints from patients regarding this tech-
nique may be decreased; in addition to this, the cancer
treatment was provided simultaneously. Chadbourne et al22
noted that macromastia problems were resolved in more
than half of the cases by reduction mammoplasty.22 This is
the most attractive aspect of the procedure, as ORM sur-
gery allows for wide excision of the tumor and provides a
solution to the patient’s chronic problem. Furthermore,
concomitant reconstructive surgery is cheaper than two
stand-alone surgeries.
Our study highlights the need to improve complications
rates for ORM. The frequency of complications during ORM
treatment in patients with macromastia is 16.5e35.7%
(Table 5). Complications due to breast reduction in
noncancerous women with macromastia are as high as one
third of cases in a series.23 The morbidity for this procedure
alone is high. Complications from ORM in patients with
breast cancer and macromastia do delay adjuvant ther-
apy.18 For example, adjuvant therapy was delayed in four
patients because of complications. We noticed that most
complications in our series occurred during early follow-up.
Most complications can be reduced with good patient se-
lection, good planning, and experience. There are many
arguments for the benefits and disadvantages of onco-
plastic breast reduction surgery. However, we recommend
ORM for patients with early stage breast cancer and
macromastia.4.3. Study limitation
ORM should not be assessed without the functional results,
but this study focused only on the oncological results.
Functional and aesthetic results are the subject of another
study.5. Conclusions
Long-term observations have demonstrated that ORM is a
very safe and appropriate treatment for early stage breast
cancer in women with macromastia, with regard to local
control and metastasis formation. The breast cancer and
macromastia problems of women should be considered in
conjunction, rather than treating the breast cancer alone.
For further results, larger and multisite studies are needed.References
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